stockrowLegend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +126.1%
- Free cash flow
- −26.8%
- Total debt
- −49.6%
Quarter to June 2026, against a year earlier
Follow LEGN
Alert me
Legend Biotech Corporation Sponsored ADR (LEGN) EBITDA
Legend Biotech Corporation Sponsored ADR's EBITDA for fiscal 2025 was −$272.4M, compared with −$176.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$19.0M. Over the past ten years it has ranged from −$437.4M (fiscal 2022) to $14.0M (fiscal 2017); the current reading is higher than 44% of that period. Legend Biotech Corporation Sponsored ADR ranks 197th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$272.4M | — |
| FY2024 | −$176.3M | — |
| FY2023 | −$392.1M | — |
| FY2022 | −$437.4M | — |
| FY2021 | −$386.2M | — |
| FY2020 | −$213.5M | — |
| FY2019 | −$124.9M | — |
| FY2018 | $149.0K | (98.94%) |
| FY2017 | $14.0M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $67.4M | — |
| Mar 2026 | −$39.3M | — |
| Dec 2025 | −$10.0M | — |
| Sep 2025 | −$37.1M | — |
| 21 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. compare | $36.9M |
| LEGN Legend Biotech Corporation Sponsored ADR | −$19.0M |
| TNGX Tango Therapeutics, Inc. compare | −$137.8M |
| ABCL AbCellera Biologics Inc. compare | −$192.6M |
| EWTX Edgewise Therapeutics, Inc. compare | −$221.9M |
| DNTH Dianthus Therapeutics, Inc. compare | −$227.5M |
| DFTX Definium Therapeutics, Inc. compare | −$227.7M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$261.9M |
| RLAY Relay Therapeutics, Inc. compare | −$311.6M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on LEGN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement